In CRC, the vertical inhibition of the MAPK pathway using a BRAF inhibitor such as encorafenib and EGFR blockade is the FDA-approved second-line therapy for patients with BRAF V600-mutated advanced CRC [39,40]. The gene discussed is BRAF; the disease is colorectal carcinoma.